15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App

Mr Jun Nakai (right), Mr Jiro Yamazaki A team of generic drug developers is aiming to cut into AstraZeneca’s strong grip on the asthma and COPD space, targeting a 15% combined share on a volume basis for their generic versions...read more